PRESS DIGEST-Canada - March 27
March 27 The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
Interim results from three patients in an early-stage trial of StemCells Inc's experimental cell treatment for chronic spinal cord injury show that two of them experienced gains in "sensory function," the company said on Monday.
StemCells is using neural stem cells, technically adult stem cells, taken from the partly developed brains of fetuses and tested for qualities showing they are destined to form particular types of nerve cells.
The company said that six months after being infused with the cells all three patients have tolerated the transplantation well and there are no safety concerns.
"We clearly need to collect more data to establish efficacy, but we are encouraged," Stephen Huhn, vice president at StemCells, said in a statement. He also said the company is pushing ahead with plans to dose patients with incomplete spinal cord injuries.
The initial phase of the trial involved patients with complete injuries and no neurological function below the level of the spinal injury.
Changes in sensitivity to touch, heat and electrical stimuli were observed in areas below the level of injury in two of the patients, while no changes were seen in the third patient, the company said.
(Reporting By Deena Beasley; editing by Andrew Hay)
* Allergan and Paratek announce positive results from two phase 3 trials of sarecycline for the treatment of moderate to severe acne